SCHEMBL2353652

SCHEMBL2353652

CCCc1nnc(Cl)cc1-c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSTP1 P09211 2/20 0.50
PRMT5 O14744 2/20 0.44
GSK3B P49841 1/20 0.43
MGAM O43451 3/20 0.42
GAA P10253 3/20 0.42
SI P14410 3/20 0.42
MGAM2 Q2M2H8 3/20 0.42
MEN1 O00255 2/20 0.42
NPC1 O15118 2/20 0.42
KMT2A Q03164 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
POLB P06746 1/20 0.42
RAB9A P51151 1/20 0.42
MAOB P27338 2/20 0.41
PPARG P37231 1/20 0.41
LTA4H P09960 1/20 0.41
EPHX2 P34913 1/20 0.41
ENPP3 O14638 1/20 0.40
ENPP1 P22413 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2352787 0.93 GSTP1 (0.48) GSTP1PRMT5GSK3BMGAMGAA
SCHEMBL14311898 0.77 MCL1 (0.51) GSTP1GSK3BMAOBPPARGLTA4H
SCHEMBL2346170 0.77 TSHR (0.50) MGAMGAASIMGAM2MEN1
SCHEMBL2352489 0.77 GSTP1 (0.51) GSTP1PRMT5MGAMGAASI
SCHEMBL2347314 0.75 PRMT5 (0.43) GSTP1PRMT5NPC1RAB9AMAOB
Hydrochloric Acid SCHEMBL2352013 0.74 PRMT5 (0.43) GSTP1PRMT5NPC1RAB9AMAOB
SCHEMBL2382685 0.72 BCHE (0.44) GSTP1
SCHEMBL2348105 0.72 KCNH2 (0.46) GSTP1LTA4HCYP1A2CYP2C19
Hydrochloric Acid SCHEMBL2347860 0.72 KCNH2 (0.46) GSTP1LTA4HCYP1A2CYP2C19
SCHEMBL8615437 0.71 RAB9A (0.57) GSTP1PRMT5MGAMGAASI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2536283-B1 PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF TRANSTECH PHARMA LLC (US) 2015-07-29 EP disclosed
US-9045461-B2 Phenyl-heteroaryl derivatives and methods of use thereof TRANSTECH PHARMA, LLC (US) 2015-06-02 US disclosed
US-20140206660-A1 Phenyl-Heteroaryl Derivatives and Methods of Use Thereof TRANSTECH PHARMA, LLC (US) 2014-07-24 US disclosed
US-8741900-B2 Phenyl-heteroaryl derivatives and methods of use thereof TRANSTECH PHARMA, LLC (US) 2014-06-03 US disclosed
US-20130197007-A1 Phenyl-Heteroaryl Derivatives and Methods of Use Thereof TRANSTECH PHARMA, INC. (US) 2013-08-01 US disclosed
US-8431575-B2 Phenyl-heteroaryl derivatives and methods of use thereof TRANSTECH PHARMA, INC. (US) 2013-04-30 US disclosed
EP-2536283-A1 PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF TransTech Pharma, Inc (US) 2012-12-26 EP disclosed
US-20110230458-A1 PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF TRANSTECH PHARMA, INC. (US) 2011-09-22 US disclosed
WO-2011103091-A1 PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF TRANSTECH PHARMA, INC. (US) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140206660-A1 Phenyl-Heteroaryl Derivatives and Methods of Use Thereof AGER, NOD2, GPBAR1 GSTP1 190/4885PRMT5 2427/4885GSK3B 781/4885
US-20110230458-A1 PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF AGER, PSEN2, PSEN1 GSTP1 121/4885PRMT5 1779/4885GSK3B 522/4885
US-20130197007-A1 Phenyl-Heteroaryl Derivatives and Methods of Use Thereof AGER, PSEN2, PSEN1 GSTP1 121/4885PRMT5 1779/4885GSK3B 522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.